Flow-Mediated Dilation Test Market Global Report 2026

The flow-mediated dilation test market size has grown strongly in recent years. It will grow from $0.07 billion in 2025 to $0.08 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases and atherosclerosis, rising awareness about early cardiovascular risk assessment, growing demand for non-invasive diagnostic procedures, increasing adoption of vascular health monitoring in clinical research, rising utilization of ultrasound-based endothelial function evaluation.

The flow-mediated dilation test market size is expected to see strong growth in the next few years. It will grow to $0.1 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing adoption of AI-based vessel measurement solutions, growing demand for personalized cardiovascular risk prediction, rising integration of advanced imaging software with diagnostic systems, increasing expansion of preventive healthcare screening programs, growing clinical adoption of automated endothelial assessment technologies. Major trends in the forecast period include increasing adoption of automated flow-mediated dilation analysis for faster endothelial function assessment, growing integration of advanced ultrasound imaging technologies for improved vascular measurement accuracy, rising demand for non-invasive cardiovascular disease risk evaluation methods, increasing use of endothelial function testing for early detection of vascular abnormalities, growing adoption of standardized clinical protocols for flow-mediated dilation testing.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the flow-mediated dilation test market going forward. Cardiovascular diseases refer to a group of disorders that affect the heart and blood vessels, including coronary artery disease, stroke, heart failure, and peripheral arterial disease. The prevalence of cardiovascular diseases is increasing due to the growing occurrence of lifestyle-related risk factors such as obesity, diabetes, hypertension, physical inactivity, and unhealthy dietary patterns. The flow-mediated dilation test market supports cardiovascular disease management by facilitating the early detection of endothelial dysfunction, enabling healthcare providers to identify cardiovascular risks before the development of structural vascular damage and supporting timely preventive interventions. For instance, in October 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, cardiovascular disease resulted in 919,032 deaths in 2023, representing approximately one in every three deaths. Therefore, the rising prevalence of cardiovascular diseases is contributing to the growth of the flow-mediated dilation test market.

The growing incidence of diabetes and obesity is expected to drive the growth of the flow-mediated dilation test market going forward. Diabetes and obesity are chronic metabolic conditions in which diabetes is characterized by consistently elevated blood glucose levels, while obesity involves excessive accumulation of body fat that increases the risk of cardiovascular disease, hypertension, and other long-term health complications. The incidence of diabetes and obesity is increasing due to sedentary lifestyles that have decreased physical activity levels and heightened the risk of metabolic disorders. The flow-mediated dilation test supports the management of diabetes and obesity by enabling early evaluation of endothelial dysfunction, detecting cardiovascular risks before the progression of clinical disease, and assisting clinicians in monitoring vascular health throughout treatment. For instance, in February 2026, according to the National Diabetes Audit (NDA) 2024-25 published by the Government of the United Kingdom, a UK-based government department, 43.0% of individuals with type 1 diabetes in England received all eight recommended care processes during the financial year ending March 2025. Therefore, the growing incidence of diabetes and obesity is contributing to the growth of the flow-mediated dilation test market.

The increasing incidence of comorbidities is expected to drive the growth of the flow-mediated dilation test market going forward. Comorbidities refer to the occurrence of two or more chronic health conditions, including diabetes, hypertension, obesity, and chronic kidney disease, within the same individual. The incidence of comorbidities is increasing due to aging populations, sedentary lifestyles, and the rising burden of chronic diseases. Flow-mediated dilation tests support the management of patients with multiple comorbid conditions by enabling early assessment of endothelial dysfunction, identifying increased cardiovascular risk, and assisting clinicians in monitoring vascular health before the occurrence of major cardiovascular events. For instance, in August 2025, according to the International Journal of Population Data Science (IJPDS), a UK-based scientific journal, the average number of comorbidities was higher among individuals from the most deprived population groups compared with those from the least deprived population groups (1.84 vs. 1.49; p < 0.001). Additionally, 28.6% of people with multiple sclerosis (pwMS) in the most deprived areas had more than three comorbidities, compared with 20.6% of those in the least deprived areas. Therefore, the increasing incidence of comorbidities is contributing to the growth of the flow-mediated dilation test market.

Major companies operating in the flow-mediated dilation test market report are Canon Medical Systems, Siemens Healthineers AG, GE HealthCare, Koninklijke Philips N.V., Mindray Medical, D.E. Hokanson Inc, Quipu Srl, Vascular Diagnostics, UNEX Corporation.

North America was the dominant region in the flow-mediated dilation test market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the flow-mediated dilation test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the flow-mediated dilation test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.